The study hypothesis is that the addition of zevalin radioimmunotherapy to the conditioning
regimen given prior to BEAM high-dose chemotherapy and autologous stem cell transplantation
in patients with aggressive lymphoma will reduced disease recurrence rate and improve overall
and disease-free survival.
Phase:
Phase 3
Details
Lead Sponsor:
Sheba Medical Center
Collaborators:
City of Hope Medical Center University of Göttingen VU University Medical Center